CD38

Across TCGA pan-cancer cohorts, CD38 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CD38 data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CD38 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD38 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where CD38 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.754	0.394	<.001	34	view →
PDAC	DFS	Tertile	II,III,IV	0.881	0.585	.001	26	view →
CCRCC	OS	Tertile	III,IV	0.750	1.000	.020	3	view →
GBM	OS	Median	All	0.459	0.584	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CD38–LUAD (DFS)

Open the LUAD breakdown →